Alipogene tiparvovec: A review of its use in adults with familial lipoprotein lipase deficiency

Drugs

Volumn 75, Issue 2, 2015, Pages 175-182

  Scott, Lesley J ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; CHYLOMICRON; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACUTE ABDOMEN; ADULT DISEASE; AUTOSOMAL RECESSIVE DISORDER; BURNING SENSATION; CHILL; CONTUSION; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FAMILIAL LIPOPROTEIN LIPASE DEFICIENCY; FATIGUE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LEG EDEMA; LEG PAIN; LIPAEMIA RETINALIS; LIPEMIA RETINALIS; LUNG EMBOLISM; MYALGIA; OUTCOME ASSESSMENT; PANCREATITIS; PULMONARY HYPERTENSION; RARE DISEASE; RETINA DISEASE; REVIEW; RISK ASSESSMENT; STABLE EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA; ADULT; ADVERSE EFFECTS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HYPERLIPOPROTEINEMIA TYPE I; PROCEDURES;

ADULT; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I;

EID: 84925511283     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0339-9     Document Type: Review

References (34)

1. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310-20.
2. Munigoti SP, Rees A. Hypertriglyceridaemia, LPL deficiency and pancreatitis: pathogenesis and therapeutic options. Brit J Diabetes Vasc Dis. 2011;11(3):107-12.
3. Bruno M. Gene therapy coming of age: prevention of acute pancreatitis in lipoprotein lipase deficiency through alipogene tiparvovec. Eur Gastroenterol Hepatol Rev. 2010;6(1):48-53.
4. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010;11(1):55-60.
5. Tong G-X, Geng Q-Q, Chai J, et al. Association between pancreatitis and subsequent risk of pancreatic cancer: a systematic review of epidemiological studies. Asian Pac J Cancer Prev. 2014;15(12):5029-34.
6. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
7. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract. 2012;66(3):270-80.
8. Burnett JR, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser447X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther. 2009;11(6):681-91.
9. Rip J, Nierman M, Sierts J, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther. 2005;16(11):1276-86.
10. European Medicines Agency. Glybera (alipogene tiparvovec): summary of product characteristics. 2013. http://www.ema.europa.eu. Accessed 9 Oct 2014.
11. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012;20(10):1831-2.
12. Haddley K. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today. 2013;49(3):161-70.
13. Rip J, Sierts JA, Vaessen SF, et al. Adeno-associated virus LPLS447X gene therapy in LDL receptor knockout mice. Atherosclerosis. 2007;194:55-61.
14. Rip J, van Dijk KW, Sierts JA, et al. AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim Biophys Acta. 2006:1163-8.
15. Ross C, Twisk J, Bakker A, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther. 2006;17:487-99.
16. Ross C, Twisk J, Meulenberg J, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum Gene Ther. 2004;15:906-19.
17. Ross CJ, Guoqing L, Kuivenhoven JA, et al. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol. 2005;25:2143-50.
18. Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361-9.
19. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28(12):2303-4.
20. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med. 2013;19(7):889-91.
21. Salmon F, Grosios K, Petry H. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev Clin Pharmacol. 2014;7(1):53-5.
22. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10):2077-86.
23. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol. 2014;5:82.
24. Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein deficiency gene therapy. Hum Gene Ther. 2014;25(3):180-8.
25. European Medicines Agency. European public assessment report: Glybera. 2012. http://www.ema.europa.eu. Accessed 20 Oct 2014.
26. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol. 2014;5:350.
27. Mingozzi F, Maus M, Hui D, et al. CD8(+) responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-22.
28. Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated gene expression J Clin Invest. 2013;123(12):5310-8.
29. Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635-44.
30. Gaudet D, Stroes E, Bruno M, et al. Gene therapy with alipogene tiparvovec (Glybera®) for the prevention of LPLD induced pancreatitis: follow-up data suggests long-term clinical benefit [abstract]. Atherosclerosis. 2014;235(2):e13.
31. Twisk J, Frisch F, Ferreira V, et al. Long-term transgene expression and biological effect following IM administration of AAV1-LPLS447X to LPL deficient patients [abstract no. 55]. Mol Ther. 2012;20(Suppl 1):S23.
32. De Wal J, Dery S, Gagne C, et al. Alipogene tiparvovec (AAV1-LPLS447X gene therapy) is long-term safe and efficacious in patients with lipoprotein lipase deficiency [abstract no. O-057]. J Inherit Metab Dis. 2011;34(Suppl 3):S233.
33. uniQure. uniQure's Glybera first gene therapy approved by European Commission [media release]. 2012. http://www.uniqure.com. Accessed 9 Oct 2014.
34. Aalbers CJ, Tak PP, Vervoordeldonk MJ. Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep. 2011;3(1).